Neuland Laboratories Limited — Q1 FY26 earnings call

Call held 31 Jul 2025

Management summary

Neuland Labs reported a challenging Q1 FY26, with a significant 32.4% YoY revenue decline due to the lumpy nature of order flows in its CMS and GDS segments. This top-line weakness led to severe operating deleverage, causing a sharp fall in profitability. Despite the poor start, management maintained its full-year growth outlook, banking on the commercialization of a new CMS molecule and the ramp-up of its new Unit 3 production block in the latter half of FY26. The focus remains on strategic investments in peptides and capacity expansion to drive future growth.

Highlights

  • Total Income was ₹300.6 crores, a sharp decrease of 32.4% YoY from ₹444 crores in Q1FY25.

  • EBITDA stood at ₹42.1 crores with an EBITDA margin of 14.4%, significantly impacted by operating deleverage.

  • Profit After Tax (PAT) declined to ₹13.7 crores, compared to ₹98.3 crores in the same period last year.

  • Quarterly EPS was ₹10.7 per share.

  • Gross Margin remained relatively stable at 55.3% compared to 56.1% in Q1FY25.

  • The CMS (Custom Manufacturing Solutions) business contributed approximately 44% to the quarter's revenue.

  • Free Cash Flow was negative at -₹66 crores for the quarter, impacted by higher inventory.

  • Management reiterated confidence in achieving FY26 growth objectives despite the weak start, expecting a stronger second half.

Concerns

  • Quarterly Revenue Volatility (Lumpiness)

  • Operating Deleveraging

Key financials

  1. Total Income ₹300.6 Cr -32.4%YoY
  2. EBITDA ₹42.1 Cr
  3. EBITDA Margin 14.4%
  4. Gross Margin 55.3%
  5. PAT ₹13.7 Cr -86.1%YoY
  6. EPS ₹10.7
  7. Free Cash Flow ₹-66 Cr

What they filed

Q1 FY27: revenue up 119.1%, net profit up 950.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue311 398 328 293 514 +65%440 +11%776 +137%642 +119%
EBITDA61 86 51 34 155 +154%77 −10%307 +502%223 +556%
Net profit32 101 28 14 96 +200%40 −60%213 +661%147 +950%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • CMS (Custom Manufacturing Solutions)
    44% Revenue Contribution

Guidance & targets

Capex

  • Total Capex Capex · FY26 · High confidence around Rs.250 crores
    So the CAPEX this year would be around Rs.250 crores.

    — Abhijit Majumdar

Growth

  • Long-term Revenue CAGR Growth · next 3-5 years · Medium confidence 20%
    Second is, we have also mentioned in the past that over 3-5 years, 20% CAGR is a reasonable number to look at for a company like Neuland and the kind of phase that we are.

    — Saharsh Davuluri

  • FY26 Revenue Growth Growth · FY26 · Low confidence Strong growth
    Strong growth is the word that we are leaving you with. So please forgive us for not being more specific than that.

    — Saharsh Davuluri

Pipeline

  • New Molecule Commercialization Pipeline · FY26 · High confidence 1 new molecule
    As I had just explained in the opening remarks, we expect another molecule to be commercialized in the course of this year.

    — Saharsh Davuluri

Capacity

  • Peptide Facility Completion Capacity · next financial year · Medium confidence Completion of new facility
    we expect the new facility for peptides to be completed in the next financial year.

    — Saharsh Davuluri

Margin

  • Margin Recovery Margin · FY26 · Low confidence Recovery from suppressed levels
    Yes, I think we see margins also recovering because the margins have been suppressed because of the poor sales.

    — Saharsh Davuluri

Risks & concerns

  • Quarterly Revenue Volatility (Lumpiness)

    high

    Management repeatedly stressed that the business is inherently uneven quarter-on-quarter due to order flows in CMS and specialty GDS, making short-term analysis difficult.

    Management acknowledged

  • Operating Deleveraging

    high

    The sharp drop in Q1 revenue directly led to margin compression. Margin recovery is highly dependent on achieving revenue growth in subsequent quarters.

    Management acknowledged

  • Working Capital Strain

    medium

    Working capital deteriorated to 145 days of sales due to higher inventory, resulting in negative free cash flow of ₹66 crores.

    Management acknowledged

  • CMS Business Concentration

    medium

    With CMS contributing 44% of revenue and being a high-margin but lumpy business, its performance disproportionately impacts overall results.

    Analyst acknowledged

Areas of evasion (1)

  • Specific quantitative growth target for FY26

Q&A highlights

2 direct, 1 evasive
FY26 Growth Guidance Specificity Evasive
Strong growth is the word that we are leaving you with. So please forgive us for not being more specific than that.

Management refused to quantify its 'strong growth' outlook for the current fiscal year, creating uncertainty for near-term forecasts despite expressing confidence.

Asked by Neel Shah

Peptide Strategy and Competitive Differentiation Direct
I think what makes Neuland a strong player in the peptide space is the 15 plus years of experience we have had in peptide chemistry... In the space of peptides, techniques become that much more important than just knowledge of chemistry...

Provides insight into management's strategic thinking for the high-growth peptide segment, highlighting experience and technical skill as key moats over just having manufacturing capacity.

Asked by Dheeraj

Engagement with Big Pharma and Capacity Constraints Direct
So frankly speaking, we don't have a lot of experience to speak about what it takes to convert Phase-3 projects from Big Pharma. But our approach has been to kind of keep investing in capabilities, infrastructure...

Reveals a candid self-assessment of the company's current market position, acknowledging more experience with biotech firms than Big Pharma, which helps frame future growth expectations.

Asked by Chirag Shah

2 min read 5 chapters

Detailed narrative

Q1 FY26 Performance: A Story of Deleveraging

Neuland Labs reported a significantly weak start to the fiscal year, with total income falling 32.4% YoY to ₹300.6 crores. Management attributed this to the inherent lumpiness of its business, particularly in commercial CMS projects and the GDS Prime segment. This revenue decline led to severe operating deleveraging, with EBITDA margins contracting to 14.4%. Consequently, Profit After Tax (PAT) saw a steep decline to ₹13.7 crores from ₹98.3 crores in Q1FY25.

Full-Year Outlook Hinges on H2 Recovery

Despite the poor Q1 performance, management reiterated its confidence in resuming the growth trajectory for the full year FY26, using FY24 as the base. They guided for 'strong growth' but refrained from giving a specific number. The expected recovery is back-ended, contingent on the commercialization of a new CMS molecule during the year and the ramp-up of the newly capitalized production block at Unit 3, which is expected to start commercial production later in the fiscal year.

Strategic Focus on Peptides and Capacity Expansion

The company's investment in the high-growth peptide segment remains on track, with the new dedicated facility expected to be completed in the next financial year. Management emphasized their 15+ years of experience as a key competitive advantage. In parallel, Neuland is pursuing a capex of ₹250 crores in FY26, with 60% allocated to growth. This includes expanding Unit 1 by acquiring adjacent land, a strategy to add FDA-approved capacity more quickly than a greenfield project.

CMS and GDS Segment Dynamics

The Custom Manufacturing Solutions (CMS) business was the primary revenue driver, contributing ~44% of the total. Management expects continued buoyancy in this segment. The GDS (Generic Drug Substances) business was subdued. The Speciality GDS segment's performance was impacted by the reclassification of Ezetimibe to the Prime GDS segment and the phasing of dispatches for other products. Management, however, does not see any concerns for the full-year performance of the Speciality portfolio.

Working Capital and Cash Flow Pressures

The uneven order flow impacted the balance sheet, with working capital increasing to 145 days of sales due to a build-up in inventory. This resulted in a negative free cash flow of ₹66 crores for the quarter. While the company maintains a negative net debt position of ₹165 crores, the management of working capital will be a key priority going forward.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls